TERMINATED

Long COVID-19 Rehabilitation & Recovery Research Program

Conditions

Post-Acute COVID-19 Syndrome COVID-19 Long COVID, COVID-19

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to assess the physiologic, immunologic, and mental health effects of an exercise and pulmonary rehabilitation program on patients with Long COVID-19 (LC).

Official Title

Long COVID-19 Rehabilitation & Research Program

Quick Facts

Study Start:2022-02-02

Study Completion:2023-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:TERMINATED

Study ID

NCT05398692

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 90 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Long COVID-19 Infection (Documented by PCR or patient report) * Age \>= 18 years old. * At least 12 weeks since the initial COVID Infection. * One or more of the following symptom/signs: Fatigue, Dyspnea, Exercise Intolerance, Post Exertional Malaise and/or Difficulty Breathing. * Able to perform a cardiopulmonary exercise test.	* Patients is not able to perform technically acceptable pulmonary function tests and symptom-limited cardiopulmonary cycle ergometry tests. * Patients who desaturate to SpO2 \<80% on screening incremental exercise testing. * Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program. * Patients who have taken an investigational drug within one month or six half-lives (whichever is greater) prior to screening visit (Visit 1). * Pregnant or nursing women. * Women of childbearing potential who are not using a highly effective method of birth control. Female patients will be considered of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years. * Patients who are currently participating in another interventional study. * Malignancy for which the patient has undergone resection, radiation therapy, or chemotherapy within the last 2 years * Any other significant disease than COVID-19 which, in the opinion of the investigator, may i) put the patient at risk because of participation in the study, ii) influence the results of the study (e.g. Insulin or testosterone therapy, systemic corticosteroids, HIV, etc), iii) cause concern regarding the patient's ability to participate in the study.

Inclusion Criteria

Exclusion Criteria

* Long COVID-19 Infection (Documented by PCR or patient report)
* Age \>= 18 years old.
* At least 12 weeks since the initial COVID Infection.
* One or more of the following symptom/signs: Fatigue, Dyspnea, Exercise Intolerance, Post Exertional Malaise and/or Difficulty Breathing.
* Able to perform a cardiopulmonary exercise test.

* Patients is not able to perform technically acceptable pulmonary function tests and symptom-limited cardiopulmonary cycle ergometry tests.
* Patients who desaturate to SpO2 \<80% on screening incremental exercise testing.
* Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit or patients who are currently in a pulmonary rehabilitation program.
* Patients who have taken an investigational drug within one month or six half-lives (whichever is greater) prior to screening visit (Visit 1).
* Pregnant or nursing women.
* Women of childbearing potential who are not using a highly effective method of birth control. Female patients will be considered of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years.
* Patients who are currently participating in another interventional study.
* Malignancy for which the patient has undergone resection, radiation therapy, or chemotherapy within the last 2 years
* Any other significant disease than COVID-19 which, in the opinion of the investigator, may i) put the patient at risk because of participation in the study, ii) influence the results of the study (e.g. Insulin or testosterone therapy, systemic corticosteroids, HIV, etc), iii) cause concern regarding the patient's ability to participate in the study.

Contacts and Locations

Study Locations (Sites)

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Torrance, California, 90509

United States

Collaborators and Investigators

Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-02-02

Study Completion Date2023-12-31

Study Record Updates

Study Start Date2022-02-02

Study Completion Date2023-12-31

Terms related to this study

Keywords Provided by Researchers

Long COVID, COVID-19

Additional Relevant MeSH Terms

Post-Acute COVID-19 Syndrome
COVID-19